L'IMPIEGO DEL MEDROSSI-PROGESTERONE ACETATO AD ALTI DOSAGGI NELLA TERAPIE PALLIATIVA DEL CARCINOMA MAMMARIO IN FASE AVANZATA. ESPERIENZA CLINICA SU 44 CASI

Translated title of the contribution: The use of medroxyprogesterone acetate in high doses in palliative treatment of advanced mammary carcinoma (clinical experience with 44 cases)

D. Amadori, A. Ravaiolli, F. Barbanit

Research output: Contribution to journalArticle

Abstract

MAP was used in high doses (1 g/die up to a total dose of 45 - 50 g) in 44 cases of advanced mammary carcinoma (IIIrd and IVth stage of the T.N.M. classification), evaluated according to the criteria proposed by CBCG. The excellent tolerance to the drug, even at such high doses, is stressed. Therapeutic responses were best in cases of metastasis in the soft and bony tissues and in cases of pulmonary metastasis. It is pointed out that the effectiveness of the treatment is particularly evident in patients in whom the free interval has exceeded two years and in patients in the menopause for more than five years. In the light of results obtained, the possibility of introducing the drug into the therapeutic strategy of this condition is discussed.

Translated title of the contributionThe use of medroxyprogesterone acetate in high doses in palliative treatment of advanced mammary carcinoma (clinical experience with 44 cases)
Original languageItalian
Pages (from-to)3967-3980
Number of pages14
JournalMinerva Medica
Volume68
Issue number59
Publication statusPublished - 1977

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The use of medroxyprogesterone acetate in high doses in palliative treatment of advanced mammary carcinoma (clinical experience with 44 cases)'. Together they form a unique fingerprint.

  • Cite this